Skip to content

Effect of different doses of esketamine pretreatment on sufentanil-induced choking response during induction of general anaesthesia

Effect of different doses of esketamine pretreatment on sufentanil-induced choking response during induction of general anaesthesia

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300076747
Enrollment
Unknown
Registered
2023-10-17
Start date
2023-11-01
Completion date
Unknown
Last updated
2023-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Choking response induced by sufentanil during the induction phase

Interventions

C group:Normal saline 5ml
A1 group:esketamine 0.05mg/kg
A2 group:esketamine 0.10mg/kg
A3 group:esketamine 0.15mg/kg

Sponsors

Lishui People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients who had selected thyroid surgery; 2. Aged 18-65 years; 3. American Society of Anesthesiologists (ASA) Grade I ~ II; 4. Cardiac function grade I ~ II.

Exclusion criteria

Exclusion criteria: 1. Smoking history; 2. BMI is greater than 28; 3. Preoperative intracranial, intra-abdominal or intraocular pressure increased; 4. Severe respiratory diseases, such as asthma, chronic cough, lung infection; 5. History of serious nervous system and heart, lung, brain and kidney diseases (such as gastroesophageal reflux, uncontrolled hypertension, diabetes, heart disease); 6. Use cough drugs (such as ACE inhibitors) or antitussive drugs before operation; 7. Long-term drug dependence and psychotic patients; 8. Subjects with opioid allergy; 9. Severe liver function abnormality; 10. Subjects who were judged to have difficulty in respiratory tract management were rated as grade IV by modified Markov score; 11. Known or suspected to be allergic or contraindicated to various components of the study drug or other benzodiazepines, opioids, propofol, muscle relaxants, etc; 12. Those who have participated in any clinical trial as subjects within 3 months before enrollment; 13. Other conditions determined by the researcher to be unsuitable for selection.

Design outcomes

Primary

MeasureTime frame
Incidence and severity of cough;Sore throat after extubation;

Secondary

MeasureTime frame
Blood pressure;Heart rate;Pulse oxygen saturation;Nausea and vomiting;postoperative agitation;

Countries

China

Contacts

Public ContactXuqiaomin

Lishui People's Hospital

xuqiaomin810@163.com+86 189 5709 2672

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026